Recent News

• 11.11.2025 - Innovation Series
• 11.03.2025 - 2025 Q3 Earnings Call
• 11.03.2025 - 2025 Q3 Earnings Call
• 11.03.2025 - 2025 Q3 Earnings Call
• 10.01.2025 - Innovation Series
• 09.08.2025 - First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
• 09.08.2025 - Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs
• 09.08.2025 - First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
• 09.08.2025 - Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response with their LP.8.1-adapted COVID-19 Vaccine 2025-2026 Formula
• 09.05.2025 - BioNTech and DualityBio Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer

Recent Filings

• 09.08.2025 - EX-99.1 EX-99.1
• 09.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.05.2025 - EX-99.1 EX-99.1
• 09.05.2025 - 144 Report of proposed sale of securities
• 08.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.27.2025 - EX-99.1 EX-99.1
• 08.15.2025 - 144 Report of proposed sale of securities